Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.56 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 5/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.49 |
| ▸ | PIM1 | P11309 | 3/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20598729 | 0.93 | CSF1R (0.49) | NTRK1NTRK2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20598372 | 0.86 | TSHR (0.49) | NTRK1NTRK2MEN1KMT2AMAPT | |
| SCHEMBL20598423 | 0.85 | PIM1 (0.46) | NTRK1NTRK2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30501448 | 0.85 | NTRK1 (0.57) | NTRK1NTRK2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20598735 | 0.85 | NTRK1 (0.57) | NTRK1NTRK2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20598394 | 0.84 | PIM1 (0.53) | NTRK1NTRK2MAPTIRAK4PIM1 | |
| SCHEMBL20598602 | 0.84 | PIM1 (0.44) | NTRK1NTRK2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20597905 | 0.84 | CSF1R (0.44) | CSF1RIRAK4PIM1PIM3PIM2 | |
| SCHEMBL20598191 | 0.84 | CHEK1 (0.61) | NTRK1NTRK2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30501201 | 0.84 | CHEK1 (0.61) | NTRK1NTRK2MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032642-B | Kinase inhibitors and methods of making and using the same | 里格尔药品股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| CN-111032642-A | Kinase inhibitors and methods of making and using | 里格尔药品股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NTRK1 726/4885NTRK2 524/4885MEN1 3526/4885 |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NTRK1 726/4885NTRK2 524/4885MEN1 3526/4885 |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | NTRK1 730/4885NTRK2 546/4885MEN1 3076/4885 |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NTRK1 726/4885NTRK2 524/4885MEN1 3526/4885 |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | NTRK1 942/4885NTRK2 568/4885MEN1 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.